Healthcare telemedicine services company Banyan Medical Systems reported on Friday the launch of the philanthropic Telehealth Aid Programme for Hospitals (TAP4H) to enable isolation patients in hospitals to receive optimal care, while providing protection to the hospital staff.
Under the first phase of the TAP4H programme, the company pledges a USD1m investment to enable 100 isolation rooms across 20 hospitals in the US and plans to expand the programme into subsequent phases. Approved and participating hospitals will receive hardware, software, installation services and virtual care services at no cost for up to five rooms for three months.
The company added that the COVID-19 crisis demands minimal contact between patients and staff and hence introducing telemedicine to decrease the risk of infection and benefit the public.It will supplement local hospital with virtual professionals and technology to enable new use-cases. Many hospitals are currently dealing with an influx of patients and expect the surge to continue over the next several months.
Banyan also said that through its TAP4H programme, it is offering its platform to hospitals dealing with COVID-19 patients to enable isolation and treatment. These facilities can provide the best patient care through use of virtual medical staff, high-fidelity two-way video communication capabilities and healthcare-specific task coordination technology.
Using the company's telehealth services, MarinHealth, one of Banyan's partners located north of San Francisco, monitors COVID-19 patients remotely, from out-of-state medical call-centres and from virtual nursing stations within the walls of the hospital itself.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering